Viewing Study NCT06050460


Ignite Creation Date: 2025-12-25 @ 2:09 AM
Ignite Modification Date: 2025-12-27 @ 8:23 AM
Study NCT ID: NCT06050460
Status: UNKNOWN
Last Update Posted: 2023-09-22
First Post: 2023-08-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19
Sponsor: Sinovac Life Sciences Co., Ltd.
Organization:

Study Overview

Official Title: A Phase I Clinical Trial to Evaluate the Safety, Tolerance and Pharmacokinetics of A Broad-Spectrum Neutralizing Antibodies SA55 Injection of COVID-19 in Healthy Adults
Status: UNKNOWN
Status Verified Date: 2023-09
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: In this first-in-humans dose escalation study, SA55 will be evaluated for safety, tolerability, and pharmacokinetics. The study is intended to enable future studies of SA55-injection's efficacy in preventing and treating COVID-19.
Detailed Description: This is a Phase I, first time in human, randomised, double-blind, placebo-controlled, and dose escalation study.

A Screening Period of up to 14 days (Day -14 through Day 0); A Treatment Period during which participants will be resident at the hospital from Day 0, 1 day before IMP administration (on Day 1) . A Follow up Period lasting 183 days after the IMP dose.

The study will be conducted at a single study centre in Beijing, China.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: